RocheLogo.jpgRandomised controlled clinical trial of Crenezumab in Alzheimer’s Disease



What is the study about? 

A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of crenezumab in patients with prodromal to mild Alzheimer’s disease.

Who can take part?

  • Age 50-85
  • Diagnosis of prodromal or mild Alzheimer’s disease
  • Availability of a regular and significant caregiver
  • Medication stable for 3 months prior to screening, sMMSE of >22.

What is involved? 

In this study, participants will be randomized to receive one of two intravenous study options: (i) crenezumab; or (ii) placebo.  Participants will receive 26 cycles of treatment, and will be closely monitored during and after treatment over 2-3 years.  The study will include physical and neurological examinations, blood and urine tests, ECG recordings, patient and participant partner questionnaires and PET scans.

Five sub-studies are also associated with the main study.  Participants will be presented with information on the sub-studies, depending on their eligibility to take part. If they decide to take part, participants will be asked to sign a separate consent form for each sub-study.

Anticipated closing date: September 2018

How do I get involved?

If you are interested in the study or would like some more information, please contact Sally Gosling (Research Nurse) on 0193 272 3332 or 01932 722 247 or email .